Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "acquisition"

843 News Found

Lupin acquires UK-based Renascience Pharma for £12.3 million
News | April 04, 2025

Lupin acquires UK-based Renascience Pharma for £12.3 million

The portfolio includes branded injectable cephalosporines for infectious diseases


DKSH Technology acquires Korean life science firm MDxK
Supply Chain | March 31, 2025

DKSH Technology acquires Korean life science firm MDxK

The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market


Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital
Startup | March 27, 2025

Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital

The freshly infused capital will primarily be deployed towards expansion and research & development


OneSource Specialty Pharma strengthens its board by appointing new directors
People | March 13, 2025

OneSource Specialty Pharma strengthens its board by appointing new directors

These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance


Zydus to acquire majority stake in Amplitude Surgical, France
News | March 12, 2025

Zydus to acquire majority stake in Amplitude Surgical, France

Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies


Senores Pharmaceuticals to increase stake in Havix to 54.96%
News | March 12, 2025

Senores Pharmaceuticals to increase stake in Havix to 54.96%

Havix was incorporated under the laws of the State of Delaware on February 17, 2015


Syngene acquires first US biologics facility for $36.5 million
News | March 11, 2025

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million


Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics
News | March 10, 2025

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise